Physician profile
Robert D Winter
NPI 1932279007
$12,057.42
in general payments reported to CMS, 2019-2025
51 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $1,690 · 2021: $2,752 · 2022: $2,382 · 2023: $1,407 · 2024: $1,148 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847 · Travel and Lodging: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,847.16 |
| Travel and Lodging | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.42 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,189.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,166.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,025.39 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Pfizer INC. | $901.37 | 2019-2025 | |
| Astellas Pharma US INC | $874.25 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $601.72 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $552.36 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $423.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.35 | 2020-2024 | Trulance |
| Daiichi Sankyo INC. | $317.29 | 2019-2023 | Injectafer |
| Amgen INC. | $314.33 | 2019-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $297.36 | 2019-2025 | Zoryve |
| Allergan, INC. | $276.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $245.84 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.